Small-molecule and peptide inhibitors of m6A regulators
N6-methyladenosine (m6A) is a reversible mRNA modification that plays important roles in malignant tumor processes. m6A modification has emerged as a significant research focus. Studies on the functions and mechanisms of m6A and its regulatory factors across various tumors have grown increasingly co...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1629864/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849419369101131776 |
|---|---|
| author | Xiaocui Liu Xiaocui Liu Xiaocui Liu Xuefeng Kan Xuefeng Kan Xuefeng Kan |
| author_facet | Xiaocui Liu Xiaocui Liu Xiaocui Liu Xuefeng Kan Xuefeng Kan Xuefeng Kan |
| author_sort | Xiaocui Liu |
| collection | DOAJ |
| description | N6-methyladenosine (m6A) is a reversible mRNA modification that plays important roles in malignant tumor processes. m6A modification has emerged as a significant research focus. Studies on the functions and mechanisms of m6A and its regulatory factors across various tumors have grown increasingly comprehensive and in-depth. Accumulating evidence has demonstrated that m6A modifications and their associated regulatory proteins can serve as biomarkers for cancer treatment and prognosis. Consequently, there has been a surge in research on the development and application of m6A regulatory factor inhibitors, particularly regarding their efficacy and mechanisms in tumor therapy. These advancements not only enhance the understanding of their therapeutic potential in diverse cancers but also facilitate their integration with existing treatments, accelerating the design of more effective, specific, and selective inhibitors. Such efforts hold promise for advancing m6A-targeted pharmaceutical development and promoting clinical applications. This review summarizes small-molecule and peptide inhibitors of m6A regulators for malignant tumors. |
| format | Article |
| id | doaj-art-c7dca4be876c4e2dac94fac55f577003 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-c7dca4be876c4e2dac94fac55f5770032025-08-20T03:32:07ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-08-011510.3389/fonc.2025.16298641629864Small-molecule and peptide inhibitors of m6A regulatorsXiaocui Liu0Xiaocui Liu1Xiaocui Liu2Xuefeng Kan3Xuefeng Kan4Xuefeng Kan5Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Provincial Clinical Research Center for Precision Radiology and Interventional Medicine, Wuhan, ChinaHubei Province Key Laboratory of Molecular Imaging, Wuhan, ChinaDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Provincial Clinical Research Center for Precision Radiology and Interventional Medicine, Wuhan, ChinaHubei Province Key Laboratory of Molecular Imaging, Wuhan, ChinaN6-methyladenosine (m6A) is a reversible mRNA modification that plays important roles in malignant tumor processes. m6A modification has emerged as a significant research focus. Studies on the functions and mechanisms of m6A and its regulatory factors across various tumors have grown increasingly comprehensive and in-depth. Accumulating evidence has demonstrated that m6A modifications and their associated regulatory proteins can serve as biomarkers for cancer treatment and prognosis. Consequently, there has been a surge in research on the development and application of m6A regulatory factor inhibitors, particularly regarding their efficacy and mechanisms in tumor therapy. These advancements not only enhance the understanding of their therapeutic potential in diverse cancers but also facilitate their integration with existing treatments, accelerating the design of more effective, specific, and selective inhibitors. Such efforts hold promise for advancing m6A-targeted pharmaceutical development and promoting clinical applications. This review summarizes small-molecule and peptide inhibitors of m6A regulators for malignant tumors.https://www.frontiersin.org/articles/10.3389/fonc.2025.1629864/fullRNA modificationN6-methyladenosineinhibitorsmolecular targetscancer treatment |
| spellingShingle | Xiaocui Liu Xiaocui Liu Xiaocui Liu Xuefeng Kan Xuefeng Kan Xuefeng Kan Small-molecule and peptide inhibitors of m6A regulators Frontiers in Oncology RNA modification N6-methyladenosine inhibitors molecular targets cancer treatment |
| title | Small-molecule and peptide inhibitors of m6A regulators |
| title_full | Small-molecule and peptide inhibitors of m6A regulators |
| title_fullStr | Small-molecule and peptide inhibitors of m6A regulators |
| title_full_unstemmed | Small-molecule and peptide inhibitors of m6A regulators |
| title_short | Small-molecule and peptide inhibitors of m6A regulators |
| title_sort | small molecule and peptide inhibitors of m6a regulators |
| topic | RNA modification N6-methyladenosine inhibitors molecular targets cancer treatment |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1629864/full |
| work_keys_str_mv | AT xiaocuiliu smallmoleculeandpeptideinhibitorsofm6aregulators AT xiaocuiliu smallmoleculeandpeptideinhibitorsofm6aregulators AT xiaocuiliu smallmoleculeandpeptideinhibitorsofm6aregulators AT xuefengkan smallmoleculeandpeptideinhibitorsofm6aregulators AT xuefengkan smallmoleculeandpeptideinhibitorsofm6aregulators AT xuefengkan smallmoleculeandpeptideinhibitorsofm6aregulators |